Oruka Therapeutics, Inc.
ORKA
Kedudukan dalam Saham
#3292
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Harga Saham
$80.01
Disegerakkan terakhir: 2026-10-21
Modal Pasaran
$5.30B
Perubahan (1 hari)
1.16%
Perubahan (1 tahun)
200.21%
Negara
US
Perdagangan Oruka Therapeutics, Inc. (ORKA)
Kategori
Healthcare
Sejarah pecahan saham untuk Oruka Therapeutics, Inc. (ORKA)
Saham Oruka Therapeutics, Inc. (simbol: ORKA) telah mengalami sejumlah 0 pecahan saham.
Pecahan saham terkini berlaku pada Oct 22, 2026.
Satu saham ORKA yang dibeli sebelum Oct 22, 2026 kini bersamaan dengan 0 saham ORKA.
Pecahan saham terkini berlaku pada Oct 22, 2026.
Satu saham ORKA yang dibeli sebelum Oct 22, 2026 kini bersamaan dengan 0 saham ORKA.
Senarai pecahan saham
| Tahun | Pecahan | Gandaan | Gandaan Kumulatif |
|---|---|---|---|
| Tidak cukup data untuk tarikh yang disediakan. | |||
Pecahan saham untuk syarikat pesaing atau serupa
| Syarikat | Bilangan pecahan saham | Gandaan Kumulatif | Negara |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 0 | - |
CH
|